New Lens for Cataracts

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Alcon Research

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

Eligibility Criteria

This trial is for adults who need cataract surgery in both eyes, can follow the study schedule, and have less than 1.00 diopter of preoperative corneal astigmatism. It's not for pregnant or breastfeeding women, those wanting monovision correction, or anyone with certain eye conditions.

Inclusion Criteria

Willing and able to attend all scheduled study visits as required by the protocol

I am scheduled for cataract surgery on both eyes.

Other protocol-defined inclusion criteria may apply

+2 more

Exclusion Criteria

Ocular conditions as specified in the protocol

I want to correct my vision to see clearly at different distances with each eye.

Other protocol-defined exclusion criteria may apply

+1 more

Participant Groups

The study compares two types of trifocal lenses: Clareon PanOptix Pro IOL and Clareon PanOptix IOL. Participants will receive one type of lens during their planned cataract surgery to see which is safer and more effective.

2Treatment groups

Experimental Treatment

Group I: CPO Pro IOLExperimental Treatment3 Interventions

CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

Group II: CPO IOLExperimental Treatment3 Interventions

CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.